Valuation: Seres Therapeutics, Inc.

Market Cap 4.65Cr 3.98Cr 3.72Cr 3.41Cr 6.41Cr 445.17Cr 6.53Cr 44Cr 17Cr 223.1Cr 17Cr 17Cr 738.62Cr P/E 2026 *
-1.33x
P/E 2027 * -0.95x
Enterprise Value 4.65Cr 3.98Cr 3.72Cr 3.41Cr 6.41Cr 445.17Cr 6.53Cr 44Cr 17Cr 223.1Cr 17Cr 17Cr 738.62Cr EV / Sales 2026 *
3.37x
EV / Sales 2027 * 170x
Free-Float
88.52%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Seres Therapeutics, Inc.

1 day-2.35%
1 week+2.01%
Current month-5.38%
1 month-10.57%
3 months-40.34%
6 months-46.55%
Current year-69.29%
1 week 4.32
Extreme 4.315
4.74
1 month 4.32
Extreme 4.315
5.65
Current year 4.32
Extreme 4.315
16.42
1 year 4.32
Extreme 4.315
29.98
3 years 4.32
Extreme 4.315
73.4
5 years 4.32
Extreme 4.315
233.8
10 years 4.32
Extreme 4.315
770
Manager TitleAgeSince
Chief Executive Officer 70 02/03/2026
Chief Executive Officer 58 01/08/2025
President 51 02/03/2026
Director TitleAgeSince
Chairman 70 02/03/2026
Director/Board Member 50 15/01/2019
Director/Board Member 80 01/04/2015
Date Insider Type Main position Quantity % Market Cap.
17/08/26 Sell

General Counsel

-82 0.0008%
17/08/26 Sell

Director

-263 0.0027%
17/08/26 Sell

Chief Operating Officer

-64 0.0007%
Change 5-day change 1-year change 3-year change Capi.($)
-2.35%+2.01%-74.53%-93.60% 4.65Cr
+2.38%+5.57%+86.02%+115.89% 7.22TCr
+0.87%+16.32%+58.35%+97.28% 6.4TCr
-4.27%-0.99%-3.38%+468.55% 2.85TCr
+3.63%+8.62%+66.69%+23.95% 2.51TCr
-1.97%+20.38%-0.37%-5.65% 2.84TCr
-0.51%+5.11%+41.27%-12.79% 2TCr
-1.79%-4.51%+241.26%+414.48% 1.82TCr
+1.81%+0.85%+16.89%+546.06% 1.6TCr
-1.29%+6.09%+41.81%+151.24% 1.35TCr
Average -0.35%+4.98%+47.40%+170.54% 2.86TCr
Weighted average by Cap. +0.38%+7.47%+61.40%+162.40%

Financials

2026 *2027 *
Net sales 1.38Cr 1.18Cr 1.1Cr 1.01Cr 1.9Cr 132.02Cr 1.94Cr 13Cr 5.1Cr 66Cr 5.18Cr 5.07Cr 219.04Cr 3L 2L 2L 2L 4L 2.62Cr 4L 25.92L 10.1L 1.31Cr 10.27L 10.05L 4.34Cr
Net income -3.75Cr -3.21Cr -2.99Cr -2.75Cr -5.16Cr -358.7Cr -5.27Cr -36Cr -14Cr -179.77Cr -14Cr -14Cr -595.15Cr -7.9Cr -6.76Cr -6.31Cr -5.79Cr -11Cr -755.47Cr -11Cr -75Cr -29Cr -378.61Cr -30Cr -29Cr -1.25TCr
Net Debt - -
Logo Seres Therapeutics, Inc.
Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. It is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.
Employees
66
Date Price Change Volume
21/26/21 $4.570 -2.35% 74,039
19/26/19 $4.680 +7.83% 87,232
18/26/18 $4.340 -3.77% 71,418
17/26/17 $4.510 -0.66% 42,185
14/26/14 $4.540 +1.34% 37,281
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.680USD
Average target price
17.00USD
Spread / Average Target
+263.25%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MCRB Stock